Switch theme
Sign up to access all valuation multiples
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
2020
25
LTM Revenue $0.5M
LTM EBITDA n/a
-$54.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Rallybio has a last 12-month revenue of $0.5M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Rallybio achieved revenue of $0.6M and an EBITDA of -$60.4M.
Rallybio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Rallybio valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | $0.6M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$78.8M | -$60.4M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -9491% | XXX | XXX | XXX |
| Net Profit | -$66.7M | -$74.6M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -11724% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Rallybio's stock price is $0.
Rallybio has current market cap of $11.2M, and EV of -$54.1M.
See Rallybio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$54.1M | $11.2M | XXX | XXX | XXX | XXX | $-1.31 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Rallybio has market cap of $11.2M and EV of -$54.1M.
Rallybio's trades at -119.4x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Rallybio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Rallybio and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$54.1M | XXX | XXX | XXX |
| EV/Revenue | -85.1x | XXX | XXX | XXX |
| EV/EBITDA | 0.9x | XXX | XXX | XXX |
| P/E | -0.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 1.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpRallybio's NTM/LTM revenue growth is -100%
Rallybio's revenue per employee for the last fiscal year averaged $25K, while opex per employee averaged $2.4M for the same period.
Over next 12 months, Rallybio's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Rallybio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Rallybio and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | Infinity% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -9491% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -23% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $25K | XXX | XXX | XXX | XXX |
| Opex per Employee | $2.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3086% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6526% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 9612% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Rallybio acquired XXX companies to date.
Last acquisition by Rallybio was XXXXXXXX, XXXXX XXXXX XXXXXX . Rallybio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Rallybio founded? | Rallybio was founded in 2020. |
| Where is Rallybio headquartered? | Rallybio is headquartered in United States of America. |
| How many employees does Rallybio have? | As of today, Rallybio has 25 employees. |
| Who is the CEO of Rallybio? | Rallybio's CEO is Dr. Stephen Uden, M.D.. |
| Is Rallybio publicy listed? | Yes, Rallybio is a public company listed on NAS. |
| What is the stock symbol of Rallybio? | Rallybio trades under RLYB ticker. |
| When did Rallybio go public? | Rallybio went public in 2021. |
| Who are competitors of Rallybio? | Similar companies to Rallybio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Rallybio? | Rallybio's current market cap is $11.2M |
| What is the current revenue of Rallybio? | Rallybio's last 12-month revenue is $0.5M. |
| What is the current EV/Revenue multiple of Rallybio? | Current revenue multiple of Rallybio is -119.4x. |
| Is Rallybio profitable? | Yes, Rallybio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
